Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.1776 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stocks That Hit 52-Week Lows On Tuesday ↗

March 15, 2022

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...

Via Benzinga

Sangamo Therapeutics: Q4 Earnings Insights ↗

February 24, 2022

Sangamo Therapeutics (NASDAQ:SGMO) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

February 24, 2022

From Sangamo Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company ↗

February 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

February 17, 2022

From Sangamo Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗

February 08, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial ↗

February 08, 2022

Sangamo Therapeutics Inc (NASDAQ: SGMO)

Via Benzinga

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

February 07, 2022

From Sangamo Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo

January 06, 2022

From Sangamo Therapeutics, Inc.

Via Business Wire

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference

January 04, 2022

From Sangamo Therapeutics, Inc.

Via Business Wire

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy

December 12, 2021

From Sangamo Therapeutics, Inc.

Via Business Wire

Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease

December 12, 2021

From Sangamo Therapeutics, Inc.

Via Business Wire

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

November 09, 2021

From Sangamo Therapeutics, Inc.

Via Business Wire

Sangamo Therapeutics, inc (SGMO) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

SGMO earnings call for the period ending October 3, 2021.

Via The Motley Fool

Topics Earnings

Why Did Sangamo Stock Jump 20% Today? ↗

November 04, 2021

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene...

Via Benzinga

81 Biggest Movers From Yesterday ↗

November 05, 2021

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 04, 2021

Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of...

Via Benzinga

55 Stocks Moving In Thursday's Mid-Day Session ↗

November 04, 2021

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...

Via Benzinga

Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results

November 04, 2021

From Sangamo Therapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

November 04, 2021

From Sangamo Therapeutics, Inc.

Via Business Wire

Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast

October 28, 2021

From Sangamo Therapeutics, Inc.

Via Business Wire

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

August 31, 2021

From Sangamo Therapeutics, Inc.

Via Business Wire

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold ↗

September 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.